Proteome Share News (PRM)

LONDON (Dow Jones)--Diagnostics company Proteome Sciences PLC (PRM.LN) Tuesday said it developed two tests focused on aspects of Alzheimer's disease. The company, which specializes in identifying proteins that could be hallmarks of disease, said one of the tests measures levels of nine proteins in the blood linked to diagnosis of Alzheimer's and predicting the disease's progression. The second measures changes to a protein called tau, a component of characteristic "tangles" often seen in the brains of Alzheimer's patients. The test has been designed for use in evaluating the potential of new drugs that target tau. The tests were developed in collaboration with researchers at King's College, London, and information on them will be presented at an international Alzheimer's conference taking place in Hawaii this week, Proteome Sciences said. -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com (END) Dow Jones Newswires July 13, 2010 03:03 ET (07:03 GMT)